期刊文献+

变应性皮肤血管炎患者血浆血小板活化因子乙酰水解酶活性变化及其临床意义 被引量:6

Variant of PAF-AH activity in the patients with allergic cutaneous vasculitis and its clinical significance
原文传递
导出
摘要 目的探讨血浆血小板活化因子乙酰水解酶(PAF-AH)对变应性皮肤血管炎的临床意义。方法采用PAF-AH活性检测试剂盒(酶水解底物显色法)测定变应性皮肤血管炎患者疾病过程中不同阶段及健康对照组的血浆PAF-AH活性。结果变应性皮肤血管炎患者病情活动期血浆PAF-AH活性明显低于健康对照组以及缓解期的酶活性,而患者缓解期的PAF-AH活性与健康对照组比较差异无统计学意义。结论血浆PAF-AH活性水平的波动与变应性皮肤血管炎病情的发生、发展、转归具有一定的关系。 Objective To investigate the levels of plasma PAF-AH in the pathogenesis of allergic cutaneous vasculitis. Methods Ac-tivity of plasma PAF-AH in patients with different stages of allergic cutaneous vasculitis and health control were detected by PAF-AH assay kit( enzymatic hydrolysis of chromogenic substrate method) . Results The activity of plasma PAF-AH in patients with the active stage of disease was significantly lower than that of healthy controls and patients in remission stage, while there was no significant difference between that of patients in remission and healthy controls. Conclusion The fluctuation of the activity of plasma of PAF-AH has some relevance with the occurrence,development,prognosis in allergic cutaneous vasculitis. Deficiency of PAF-AH activity may be one of the pathogenesis of allergic cutaneous vasculitis.
出处 《临床军医杂志》 CAS 2015年第9期924-925,共2页 Clinical Journal of Medical Officers
关键词 变应性皮肤血管炎 血小板活化因子乙酰水解酶 活性 Allergic cutaneous vasculitis PAF-AH Activity
  • 相关文献

参考文献9

  • 1Bechler ME,Doody AM,Ha KD,et al.The phospholipase Az enzyme complex PAFAH Ib mediates endosomal membrane tubule formation and trafficking[J].Mol Biol Cell,2011,22(13):2348-2359.
  • 2Stafforini DM,Prescott SM,Mc Intyre TM.Human plasma plateletactivating factor acetylhydrolase.Purification and properties[J].J Biol Chem,1987,262(9):4223-4230.
  • 3Stafforini DM.Biology of platelet-activating factor acetylhydrolase(PAF-AH,lipoprotein associated phospholipase A2)[J].Cardiovasc Drugs Ther,2009,23(1):73-83.
  • 4毕新岭,顾军,米庆胜.血小板活化因子乙酰水解酶与相关疾病的研究[J].国外医学(内科学分册),2003,30(6):259-261. 被引量:6
  • 5Cederholm A,Svenungsson E,Stengel D,et al.Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus[J].Arthritis Rheum,2004,50(9):2869-2876.
  • 6Tjoelker LW,Wilder C,Eberhardt C,et al.Anti-inflammatory properties of a platelet-activating factor acetylhydrolase[J].Nature,1995,374(6522):549-553.
  • 7Ohnishi T,Watanabe S,Kobayashi M,et al.Serum platelet-activating factor acetylhydrolase activity in patients with atopic dermatitis[J].J Dermatol Sci,2003,33(1):70-72.
  • 8Perelman B,Adil A,Vadas P.Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy[J].Allergy Asthma Clin Immunol,2014,10(1):20.
  • 9Reyes-Quiroz ME,Alba G,Santa-Maria C,et al.Platelet-activating factor downregulates the expression of liver X receptor-αand its target genes in human neutrophils[J].FEBS J,2014,281(3):970-982.

二级参考文献15

  • 1Miwa MT, Miyake T, Yamaoka J,et al.[J ]. J Clin Invest, 1988, 82:1983-1991.
  • 2Stafforini DM, Satoh K, Atkinson DL, et al. [J].J Clin Invest, 1996, 97 : 2784-2791.
  • 3Yamada Y, Ichihara S, Izawa H, et al. [ J]. J Hum Genet, 2001,46:436-441.
  • 4Unno N, Nakamura T, Mitsuoka H, et al. [J].Ann Surg, 2002, 235:297-302.
  • 5Satoh N, Asano K, Naoki K, et al. [ J ]. Am J Respir Crit Care Med, 1999,159:974-979.
  • 6Kim JD, Baker CJ, Roberts RT, et al. [J]. Ann Thorac Surg, 2000,70:423-428.
  • 7Henderson WR Jr, Lu J, Poole KM, et al. [ J ]. J Immunol, 2000, 164:3360-3367.
  • 8Tjoelker H , Otbauer LW, Stafforini DM, et al.[J]. Biochem Biophys Acta, 2000, 1488: 102-123.
  • 9Murakami M, Kudo I. [J]. J Biochem, 2002,131:285-292.
  • 10Hattori K, Adachi H, Matsuzawa A, et al. [ J ]. J Biol Chem, 1996, 271:33032-33038.

共引文献5

同被引文献48

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部